Assessing the role of Aspartate transaminase to Platelet count ratio index (APRI) in predicting severe Dengue

·       After taking prior permission from the Head of Department of Medicine, the subjects will be recruited in the study.

·       A participant information sheet containing the particulars of the study would be given and the subjects would be explained about the objectives of the study. Informed consent will be taken from the subjects. Both (Participant Information Sheet and Informed Consent) will be made available in English and also in the local language Kannada.

·       The details of the report will be kept confidential.

·       All the patients who are above 18 years of age and positive for dengue illness which is confirmed by doing a dengue IgM antibody using a kit of National Institute of Virology, Pune or by NS1 antigen testing done using Pan bio ELISA kit and who consent for the study will be recruited to the study.

·       Demographic details including age, sex , symptoms, bleeding manifestation, comorbidities, general and systemic examination findings, laboratory investigations such as complete blood profile, renal function tests, liver function tests, c-reactive protein, electrocardiogram, chest x-ray, ultrasound abdomen and coagulation parameters will be recorded in a predesigned proforma.

·       Platelet count would be estimated using automated hematology analyser

·       APRI will be calculated using the formula mentioned

·       Patients will be classified based on the severity of dengue according to the 2009 revised WHO criteria(Figure.1) as non-severe dengue and severe dengue. The non-severe dengue group will be further categorised as dengue with warning signs and without warning signs

·       Estimation of AST and platelet count and calculation of APRI will be done for all the patients who would be recruited and comparison will be done in each of this group based on the severity.